<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154270</url>
  </required_header>
  <id_info>
    <org_study_id>COSMIC</org_study_id>
    <nct_id>NCT01154270</nct_id>
  </id_info>
  <brief_title>CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC</brief_title>
  <acronym>COSMIC</acronym>
  <official_title>Combined Therapy of Malignant Salivary Gland Tumours With IMRT and Carbon Ions: COSMIC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COSMIC trial is a prospective, mono-centric, phase II trial evaluating toxicity and
      efficacy in the combined treatment with intensity-modulated radiation therapy (IMRT) and
      carbon ion (C12) boost. Primary endpoint is mucositis ≥ CTC°3, secondary endpoints are local
      control, disease-free survival, and toxicity. Planned accrual of the trial includes 54
      patients with histologically proved (≥R1-resected, inoperable or Pn+) salivary gland
      malignancies. Treatment consists of 24 GyE carbon ions (8 fractions) and 50 Gy IMRT (2.0 Gy/
      fraction).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Local control in malignant salivary gland tumours is dose dependent. High local control rates
      in adenoid cystic carcinomas could be achieved by highly conformal radiotherapy techniques
      and particle (neutron/ carbon ion) therapy. Considering high doses are needed to achieve
      local control, all malignant salivary gland tumours probably profit from the use of particle
      therapy, which in case of carbon ion treatment, has been shown to be accompanied by only mild
      side-effects.

      Methods/ design:

      The COSMIC trial is a prospective, mono-centric, phase II trial evaluating toxicity in the
      combined treatment with intensity-modulated radiation therapy (IMRT) and carbon ion (C12)
      boost in 54 patients with histologically proved (≥R1-resected, inoperable or Pn+) salivary
      gland malignancies. Patients receive 24 GyE carbon ions (8 fractions) and IMRT (2.0 Gy/
      fraction).

      Study objectives:

      Incidence of mucositis ≥ CTC°3 will be assessed as the primary endpoint of the trial, local
      control, disease-free survival, toxicity (incl. mucositis CTC °I-II and late toxicity at 3
      years post RT)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mucositis ≥ CTC°3</measure>
    <time_frame>6-8 weeks post completion of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>local control</measure>
    <time_frame>3 years post RT</time_frame>
    <description>to evaluate local control at 3 years post RT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>6-8 weeks post completion of treatment</time_frame>
    <description>evaluation of acute radiation effects (other than mucositis CTC°C) 6-8 weeks post completion of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late toxicity</measure>
    <time_frame>3 years post radiotherapy</time_frame>
    <description>to evaluate radiation late effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3 years post treatment</time_frame>
    <description>to evaluate disease-free survival at 3 years post radiotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Malignancy</condition>
  <condition>Salivary Glands</condition>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>IMRT + C12-boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>carbon ion boost</intervention_name>
    <description>8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks</description>
    <arm_group_label>IMRT + C12-boost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed or surgically removed malignant tumour of the salivary glands
             (head and neck)

          -  Inoperable tumour

          -  G2/3

          -  Macroscopic or microscopic residual tumour (R2/ R1) or

          -  ≥T3/T4 or

          -  perineural invasion (Pn+)

          -  written informed consent

          -  pts aged 18 - 80 years

          -  effective contraception for pts in childbearing age (&lt;12 months post beginning of
             menopause)

        Exclusion Criteria:

          -  Prior radio- or chemotherapy for tumours of the head and neck

          -  Other previous malignancy within the past 5 years except prior, adequately treated
             basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix

          -  Significant neurological or psychiatric condition including dementia or seizures or
             other serious medical condition prohibiting the patient's participation in the trial
             by judgement of the investigators

          -  Legal incapacity or limited legal capacity

          -  Positive serum/ urine beta-HCG/ pregnancy

          -  Drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc W Muenter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Radiation Oncology, INF 400, 69120 Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Radiation Oncology, INF 400</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 1986 Jan-Feb;8(3):177-84.</citation>
    <PMID>3744850</PMID>
  </reference>
  <reference>
    <citation>Chen AM, Granchi PJ, Garcia J, Bucci MK, Fu KK, Eisele DW. Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):982-7. Epub 2007 Jan 22.</citation>
    <PMID>17241753</PMID>
  </reference>
  <reference>
    <citation>Gurney TA, Eisele DW, Weinberg V, Shin E, Lee N. Adenoid cystic carcinoma of the major salivary glands treated with surgery and radiation. Laryngoscope. 2005 Jul;115(7):1278-82.</citation>
    <PMID>15995521</PMID>
  </reference>
  <reference>
    <citation>Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Hinerman RW, Villaret DB. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck. 2004 Feb;26(2):154-62.</citation>
    <PMID>14762884</PMID>
  </reference>
  <reference>
    <citation>Chen AM, Bucci MK, Weinberg V, Garcia J, Quivey JM, Schechter NR, Phillips TL, Fu KK, Eisele DW. Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):152-9.</citation>
    <PMID>16904520</PMID>
  </reference>
  <reference>
    <citation>Garden AS, Weber RS, Ang KK, Morrison WH, Matre J, Peters LJ. Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. Cancer. 1994 May 15;73(10):2563-9.</citation>
    <PMID>8174054</PMID>
  </reference>
  <reference>
    <citation>Terhaard CH, Lubsen H, Van der Tweel I, Hilgers FJ, Eijkenboom WM, Marres HA, Tjho-Heslinga RE, de Jong JM, Roodenburg JL; Dutch Head and Neck Oncology Cooperative Group. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 2004 Aug;26(8):681-92; discussion 692-3.</citation>
    <PMID>15287035</PMID>
  </reference>
  <reference>
    <citation>Terhaard CH, Lubsen H, Rasch CR, Levendag PC, Kaanders HH, Tjho-Heslinga RE, van Den Ende PL, Burlage F; Dutch Head and Neck Oncology Cooperative Group. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):103-11.</citation>
    <PMID>15629600</PMID>
  </reference>
  <reference>
    <citation>Bittner N, Koh WJ, Laramore GE, Patel S, Mulligan MS, Douglas JG. Treatment of locally advanced adenoid cystic carcinoma of the trachea with neutron radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):410-4. doi: 10.1016/j.ijrobp.2008.01.016. Epub 2008 Apr 18.</citation>
    <PMID>18374509</PMID>
  </reference>
  <reference>
    <citation>Schulz-Ertner D, Nikoghosyan A, Didinger B, Münter M, Jäkel O, Karger CP, Debus J. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer. 2005 Jul 15;104(2):338-44.</citation>
    <PMID>15937907</PMID>
  </reference>
  <reference>
    <citation>Douglas JG, Koh WJ, Austin-Seymour M, Laramore GE. Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8.</citation>
    <PMID>12975266</PMID>
  </reference>
  <reference>
    <citation>Mizoe JE, Tsujii H, Kamada T, Matsuoka Y, Tsuji H, Osaka Y, Hasegawa A, Yamamoto N, Ebihara S, Konno A; Organizing Committee for the Working Group for Head-And-Neck Cancer. Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):358-64.</citation>
    <PMID>15380567</PMID>
  </reference>
  <reference>
    <citation>Huber PE, Debus J, Latz D, Zierhut D, Bischof M, Wannenmacher M, Engenhart-Cabillic R. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol. 2001 May;59(2):161-7.</citation>
    <PMID>11325445</PMID>
  </reference>
  <reference>
    <citation>Münter MW, Schulz-Ertner D, Hof H, Nikoghosyan A, Jensen A, Nill S, Huber P, Debus J. Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the treatment of incompletely and completely resected adenoid cystic carcinomas of the head and neck: initial clinical results and toxicity of treatment. Radiat Oncol. 2006 Jun 6;1:17.</citation>
    <PMID>16756669</PMID>
  </reference>
  <reference>
    <citation>Pommier P, Liebsch NJ, Deschler DG, Lin DT, McIntyre JF, Barker FG 2nd, Adams JA, Lopes VV, Varvares M, Loeffler JS, Chan AW. Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg. 2006 Nov;132(11):1242-9.</citation>
    <PMID>17116822</PMID>
  </reference>
  <reference>
    <citation>Schulz-Ertner D, Nikoghosyan A, Jäkel O, Haberer T, Kraft G, Scholz M, Wannenmacher M, Debus J. Feasibility and toxicity of combined photon and carbon ion radiotherapy for locally advanced adenoid cystic carcinomas. Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):391-8.</citation>
    <PMID>12738314</PMID>
  </reference>
  <reference>
    <citation>Schulz-Ertner D, Nikoghosyan A, Thilmann C, Haberer T, Jäkel O, Karger C, Kraft G, Wannenmacher M, Debus J. Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):631-40.</citation>
    <PMID>14751537</PMID>
  </reference>
  <reference>
    <citation>Münter M, Umathum V, Nikoghosyan A, Jensen A, Hof H, Jaekel O, et al. Combination of intensity modulated radiation therapy (IMRT) and a carbon ion boost for subtotal resected or inoperable adenoid cystic carcinomas (ACC's) of the head and neck. PTCOG meeting 2009, abstract FC84</citation>
  </reference>
  <reference>
    <citation>Krempien R, Münter MW, Timke C, Friess H, Hartung G, Herfarth KK, et al. Cetuximab in combination with intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer: a prospective phase II trial [PARC-study ISRCTN56652283]. J Clin Oncol 2007; 25 (18S) 4573</citation>
  </reference>
  <reference>
    <citation>Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.</citation>
    <PMID>10655437</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <last_update_submitted>April 23, 2013</last_update_submitted>
  <last_update_submitted_qc>April 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2013</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. MW Münter</name_title>
    <organization>Dept. of Radiation Oncology</organization>
  </responsible_party>
  <keyword>cancer of the salivary glands</keyword>
  <keyword>radiation</keyword>
  <keyword>carbon ion therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

